Home >> Pharmaceuticals >> Food & Beverage >>

Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015

Published: Apr-2015 | Format: PDF | Global Markets Direct | Number of pages: 63 | Code: MRS - 18259

Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Pipeline Review, H1 2015’, provides an overview of the Dementia Associated With Alzheimer's Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dementia Associated With Alzheimer's Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia Associated With Alzheimer's Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dementia Associated With Alzheimer's Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dementia Associated With Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dementia Associated With Alzheimer's Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dementia Associated With Alzheimer's Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Dementia Associated with Alzheimer's disease Overview 6
Therapeutics Development 7
Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview 7
Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis 8
Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies 9
Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes 10
Dementia Associated With Alzheimer's Disease - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Dementia Associated With Alzheimer's Disease - Products under Development by Companies 14
Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes 15
Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development 16
Actinogen Limited 16
Chase Pharmaceuticals Corporation 17
Eisai Co., Ltd. 18
FORUM Pharmaceuticals Inc. 19
MediPost Co., Ltd. 20
Neurodyn Inc. 21
Otsuka Holdings Co., Ltd. 22
Dementia Associated With Alzheimer's Disease - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
aripiprazole - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AVCRI-104P3 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
brexpiprazole - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CPC-201 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
E-2609 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
encenicline hydrochloride - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Gln-1062 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Neurostem - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Product Description 47
Mechanism of Action 47
R&D Progress 47
UE-2343 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Dementia Associated With Alzheimer's Disease - Recent Pipeline Updates 49
Dementia Associated With Alzheimer's Disease - Dormant Projects 59
Dementia Associated With Alzheimer's Disease - Discontinued Products 60
Dementia Associated With Alzheimer's Disease - Product Development Milestones 61
Featured News & Press Releases 61
Apr 13, 2015: EU Patent Granted - Further Extends Xanamem Protection 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 62
Disclaimer 63

List of Tables
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2015 7
Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Dementia Associated With Alzheimer's Disease - Pipeline by Actinogen Limited, H1 2015 16
Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H1 2015 17
Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H1 2015 18
Dementia Associated With Alzheimer's Disease - Pipeline by FORUM Pharmaceuticals Inc., H1 2015 19
Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H1 2015 20
Dementia Associated With Alzheimer's Disease - Pipeline by Neurodyn Inc., H1 2015 21
Dementia Associated With Alzheimer's Disease - Pipeline by Otsuka Holdings Co., Ltd., H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 27
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 31
Dementia Associated With Alzheimer's Disease Therapeutics - Recent Pipeline Updates, H1 2015 49
Dementia Associated With Alzheimer's Disease - Dormant Projects, H1 2015 59
Dementia Associated With Alzheimer's Disease - Discontinued Products, H1 2015 60

List of Figures
Number of Products under Development for Dementia Associated With Alzheimer's Disease, H1 2015 7
Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Top 10 Targets, H1 2015 24
Number of Products by Stage and Top 10 Targets, H1 2015 25
Number of Products by Top 10 Mechanism of Actions, H1 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Top 10 Routes of Administration, H1 2015 28
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29
Number of Products by Top 10 Molecule Types, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing